
Opinion|Videos|August 8, 2024
Esketamine for TRD: MOA, Application, and Adverse Events
Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD
2
Phase 3 Dermatomyositis Trial Sees Brepocitinib Meet Primary Endpoint
3
Q&A: Fear, Not Appetite Loss, Drives ARFID Eating Patterns in Food Allergy
4
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
5












































































